Abstract 52P
Background
Post mastectomy adjuvant radiotherapy (RT) is a critical part in management of breast cancers. Left sided breast cancer cases are at higher risk of developing radiation induced cardiac morbidities. Increased radiation dose to the heart and lung may cause non-breast cancer related mortality and reduce the survival benefits from breast cancer RT. We designed a prospective clinical trial to examine the impact of CPAP on heart and lung during left sided post mastectomy radiotherapy.
Methods
24 left sided post mastectomy patients, after prior consent were included in this study. All patients were simulated in free breathing technique, followed by using CPAP (target pressure 10 to 15 cm of H20). Contouring was done using RTOG guideline. Heart and lung volumes were noted. IMRT virtual plans for both of these techniques were made for all patients using Monaco 5.51.10 software. Mean heart dose, Heart V25, Ipsilateral Lung mean dose, V5, V10, V20 were measured. Mean ± Std values were assessed using Students’ t-test.
Results
Compared to FB, CPAP showed significant difference. Mean heart distance from sternal notch was 6.2 cm and 7.2 cm ;p Value: 0.032 and Mean heart volumes were 354cc and 387cc in the CPAP and FB arms respectively;pValue: 0.665 . Mean left lung volumes were 1281 cc and 1398 cc respectively ;pValue 0.038 favouring CPAP arm. Similarly mean right lung volume of 1552 cc was significantly higher in CPAP arm compared to 1178 cc in FB arm (pValue : 0.041). Heart Dmean was found to be statistically better in CPAP arm (2.5 Gy) compared to FB arm (3.4 Gy) (p Value 0.020). Average V25 of heart was significantly superior in CPAP arm compared to FB arm (0.23% and 2.24% respectively,p Value 0.035). Heart Dmean was 3.1 Gy in CPAP arm compared to 3.7 Gy in FB arm ,pValue: 0.677. Similar result was found for heart V25. CPAP and FB Ipsilateral lung mean dose (6.69Gy and 6.32Gy, pValue: 0.62), Lung V5 (29% and 27.3%, p Value: 0.77), Lung V10 (16.3% and 16.4%, pValue: 0.78), Lung V20 (11.2% and 11.89%, p value 0.22) didn’t show statistical difference.
Conclusions
CPAP is an excellent tool for cardiac sparing in left sided post mastectomy breast cancer cases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract